|[January 10, 2013]
Research and Markets: The Pricing and Reimbursement Environment for Respiratory Disease Therapies
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/kg74wj/special_report)
has announced the addition of Decision Resources, Inc's new report
"Special Report: The Pricing and Reimbursement Environment for
Respiratory Disease Therapies" to their offering.
Common respiratory diseases such as asthma and chronic obstructive
pulmonary disease (COPD) make up a large and varied pharmaceutical
market sector. These diseases also impose a significant burden on
patients, providers, and payers, putting them front and center as the
subjects of efforts to improve patient outcomes while containing costs
to health systems. Governments and other payers are compelled to invest
substantial resources in the management of these disorders. At the same
time, payers continue to scrutinize the cost-to-benefit ratio o all
therapeutic options very closely. The pharmaceutical industry will need
to make a clear case for the role of drug therapy as a critical
component in the effective management of respiratory disorders.
Markets covered: United States, France, Germany, Italy, Spain,
United Kingdom, Japan.
Healthcare system overviews: Healthcare sector reforms; roles of
public and private payers; formulary decision makers.
Epidemiology: Prevalence of key respiratory diseases
and drug-treatment rates in the seven major pharmaceutical markets in
2010 and 2020.
Pharmaceutical pricing: Procedures for setting prices; use of
external reference pricing.
Admission to reimbursement: Bodies involved in reimbursement
decision making; reimbursement procedures; reimbursement rates.
Cost containment: Reference pricing; prescribing restrictions;
measures to promote greater use of generics.
Primary research: Results from a Web-based survey of 105 U.S.
pulmonologists and primary care physicians (PCPs) who manage patients
with respiratory diseases.
Outlook: Future pricing and reimbursement landscape for
respiratory drug therapies.
Exhibits: 33 tables and figures showing comparative
drug prices, respiratory disease epidemiology, market data, healthcare
system characteristics, U.S. physician survey data, and payer coverage.
For more information visit http://www.researchandmarkets.com/research/kg74wj/special_report
Source (News - Alert): Decision Resources, Inc
[ Back To Smart Grid Home's Homepage ]